Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 18, 2022 08:00 ET | Source: Levo Therapeutics, Inc.

Levo Therapeutics Receives Complete Response Letter From FDA for Its New Drug Application for LV-101 (Intranasal Carbetocin) for the Treatment of Prader-Willi Syndrome

CHICAGO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Levo Therapeutics, Inc., a biotechnology company dedicated to using genetic insights to advance treatments for Prader-Willi syndrome (PWS) and related...